---
schema_version: "secwatch.filing_event.v1"
accession: "0001323885-22-000055"
form_type: "8-K"
ticker: "ATRC"
cik: "0001323885"
company_name: "AtriCure, Inc."
filed_at: "2022-05-03T23:59:59+00:00"
generated_at: "2026-06-26T01:19:18.269325+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AtriCure Q1 revenue $74.6M (+25.8% YoY); guides FY22 rev $318-330M

## Summary
- Revenue $74.6M, up 25.8% YoY; U.S. $62.3M (+23.8%), intl $12.3M (+37.2%).
- Gross margin 74.5% vs 75.1% YoY; operating loss narrowed to $14.2M from $15.9M.
- GAAP net loss $0.33/share; adjusted loss $0.33/share; adj EBITDA loss $4.2M.
- FY 2022 rev guidance $318-330M (+16-20%); adj EPS loss $1.07-$1.12.
- CEO cites broad-based growth; EPi-Sense adoption, Cryo Nerve Block expansion, EnCompass launch.

## SEC filing metadata
- accession: 0001323885-22-000055
- form_type: 8-K
- ticker: ATRC
- cik: 0001323885
- company_name: AtriCure, Inc.
- filed_at: 2022-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1323885/000132388522000055/0001323885-22-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1323885/000132388522000055/atrc-20220503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001323885-22-000055
- JSON: https://secwatch.observer/filing/0001323885-22-000055.json
- Plain text: https://secwatch.observer/filing/0001323885-22-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.